ROCHE REMAINS A BELLWETHER, DESPITE RECENT (R&D) JITTERS (ADD; 14% UPSIDE)
19/09/22 -" Since early 2022, an already fragile global economy (surfing on monetary excesses) has faced several challenges – spiralling inflation and supply-chain disruptions – due to the war in Europe, ..."
Pages
66
Language
English
Published on
19/09/22
You may also be interested by these reports :
04/11/25
The Q3 operating profitability exceeded expectations, though sales fell short of consensus. The management reaffirmed its full-year guidance. While ...
03/11/25
BioNTech reported mixed Q3 results. Sales significantly exceeded market expectations, but the operating loss was higher than anticipated. The 2025 ...
31/10/25
Novo has locked horns with Pfizer by proposing to acquire obesity-focused Metsera, after Pfizer had made an offer in September 2025. Metsera’s ...
30/10/25
While Q3 sales fell marginally short of the street’s expectations, a healthily growing high-margin Biosimilars segment led to the 2025 profitability ...